Skip to main content

Table 1 The main characteristics of the eligible studies

From: Prognostic value of Kindlin-2 expression in patients with solid tumors: a meta-analysis

Study (Author and year) Country size Tumor type Sample type Method (antibody data) Negative control Expression location Cut-off value: (intention) or (IPS = x * y) High expression ratio: n/N (%) Follow-up time: mean (min–max) (mon) Survival outcome Conclusion (UA/MA) Multivariate analysis HR extraction NOS score
Yoshida et al. 2017 (I) [14] Japan 79 PDAC ac (Ca)
Startle (St)
IHC (M, Merck Millipore) NT + NP NR 50% Ca: 54/79 (68%)
St: 49/79 (62%)
NR OS; RFS OS; RFS NS; NS; NS; P No KM plot 8
Zhan et al. 2015 [15] China 31 PDAC ac IHC (Millipore) PBS NR 50% 15/31 (48%) 47 (3–73) OS P No P-value 7
Mahawithitwong et al. 2013 [16] Japan 95 PDAC sf IHC (R, Protein TechGroup, 1:100) NR NR (4 * 3) 4/12 34/95 (64.2%) 24 (3–136); 14 (0–136) OS; DFS P/NS; P/− Yes Cox, P-value 7
Cao et al. 2015 (II) [17] China 110 ESCC scc IHC (M, Origen,1:50) NR C + N (3 * 4) NR 34/65 (52%) 36.5 (0–148.7) OS; DFS −/P; −/P Yes Cox 6
Cao et al. 2015 (III) [17] China 147 ESCC scc IHC (M, Origen,1:50) NR C + N (3 * 4) NR 20/64 (31%) 28.8 (27–72) OS; DFS P; P Yes Cox 6
Wu et al. 2017 [18] China 203 BC sf IHC (M, Santa Cruz, 1:500) PBS NR (3 * 4) 6/12 109/203 (54%) 64 (49–78) OS; CSS; DFS P/P; P/−; P/− Yes Cox 6
Papachristou et al. 2008 [19] Greece etc. 60 CHS sf IHC (M, homemade, 1/50) TBS C 33% 51/60 (85%) 67.9 (40.9, 2–180) OS P No P-value 8
Ge et al. 2015 [20] China 72 HCC ac IHC (R, ab152106, 1:100) PBS NR (4 * 3) 4/12 43/72 (60%) NR (17.96–43.11) OS; DFS P/P; P/P Yes Cox 7
Lin et al. 2017 [21] China 127 HCC ac IHC (M, MAB2617, Billerica, 1:100) NR C (3 * 4) 4/12 103/127 (81%) 22 (1–94) OS P/P Yes Cox 8
Ning et al. 2017 [22] China 100 OSS Sarcoma IHC (R, Millipore, 1:150) PBS N (3 * 4) 4.56/12 51/100 (51%) 29.82 (5.26–38.89) OS; DFS P/P; P/P Yes Cox 7
Ou et al. 2016 [23] China 188 Glioma Carcinoma IHC (1:100) NR NR 4/12 132/188 (70%) NR (0–39) OS P/P Yes Cox 8
Ren et al. 2014 [24] China 113 sEOC scc IHC (R, Dako, 1:2000) PBS NR (4 * 4) 12/16 91/113 (80%) NR OS; PFS N/NS; N/N Yes KM-plot 6
Shen et al. 2012 [25] China 40 GC ac WB (R, ab74030, Abcam, 1:600) actin NR Ratio: K2/actin > 2 22/40 (55%) 37.1 (5–77) OS; PFS P/NS; P/P Yes Cox 8
Li et al. 2017 [26] China 109 ccRCC ac IHC (M, Millipore) NT C 50% 70/109 (64%) 69 (0.94–82) OS P/NS Yes Cox 7
Yan et al. 2016 [27] China 336 ccRCC ac IHC (M, ab117962, Abcam, 1:100) NR NR (3 * 3) 4/9 199/336 (59%) NR (10–60) OS; DFS −/P; −/P Yes Cox 7
  1. (I) This article (Yoshida [14]) was listed two cohort study because the sample types contains cancer tissue and startle cell. (II) and (III) This article (Cao [17]) included patients from generation dataset (II) and validation dataset (III). Antibody data mainly contains the species (mouse, rabbit), code, manufacturer, and concentration ratio
  2. n: number of patients; PDAC: pancreatic ductal adenocarcinoma; ESCC: esophageal squamous cell carcinoma; BC: bladder cancer; CHS: chondrosarcoma; HCC: hepatocellular carcinoma; OSS: osteosarcoma; sEOC: serous epithelial ovarian cancers; GC: gastric cancer; ccRCC: clear cell renal cell carcinoma; ac: adenocarcinoma; Ca: cancer tissue, St: startle cell; sf: stromal fibroblasts; scc: squamous cell carcinoma; IHC: immunohistochemistry; WB: Western Blot; NR: no report; NT: non-cancer tissue; NP: non-tumor patient; PBS: phosphate buffered solution; TBS: triethanolamine buffered solution; C: cytoplasm, N: cellular nucleus; IPS: immunohistochemical positive score; x: up-limit of the averaged staining intensity score; y: up-limit of the score standing for stained cells proportion; *: multiplication of the two score; Ratio: the ratio of gray value; UA: univariate analysis; MA: multivariate analysis; NS: not significant, P: positive for the conclusion that Kindlin-2 high expression is associated with poor prognostic outcome, N: negative for the conclusion; Cox: Cox proportional-hazards model; NOS: the Newcastle–Ottawa Quality Assessment Scale